DGAP-News: The World's First Toxin Free Dynamic Wrinkle Treatment is Approved in Europe
(firmenpresse) - myoscience
01.02.2013 08:00
---------------------------------------------------------------------------
iovera Gains CE Mark
IMCAS, Paris, 2013-02-01 08:00 CET (GLOBE NEWSWIRE) --
myoscience, inc. has announced the release of iovera following CE mark approval
on 24 January 2013. IMCAS marks the launch of the iovera brand to medical
aesthetic professionals. Developed and produced by myoscience, iovera is a
revolutionary treatment for dynamic facial lines, which provides an immediately
visible reduction in wrinkles without leaving any toxins or chemicals behind in
the body. The treatment is based upon myoscience's platform technology, Focused
Cold Therapy (tm). It works by using the body's natural response to cold to
temporarily relax the facial muscles that cause wrinkles.
Clint Carnell, CEO of myoscience, says, 'CE approval and launch of the iovera
brand at IMCAS marks a significant milestone for myoscience in paving the way
to commercialize our product in Europe. iovera is an exciting advance meeting
the clear need for a toxin-free treatment while expanding treatment choice.'
Speaking at IMCAS, Daniel Cassuto, MD, professor of plastic surgery at the
University of Catania in Milan says: 'iovera is an exciting advance in medical
aesthetics treatments and is a welcome addition to the physician's tool box. I
know from experience that there are a significant number of patients for whom
toxin treatments are not an option; iovera meets the needs of patients today.'
Focused Cold Therapy(tm) delivers precise cold to peripheral nerve tissue. Nerves
treated with this technology undergo a predictable period of dormancy, followed
by complete restoration of function. iovera treats forehead lines immediately
with results lasting up to 4 months. The procedure is designed for use in a
minor treatments room and takes about 15 minutes. iovera will be first
available in select centres of excellence before becoming more widely available
across Europe throughout 2013.
For more information about iovera, visit www.myoscience.com.
About myoscience
Silicon Valley, California-based myoscience is a privately-held medical device
company committed to making its platform technology, Focused Cold Therapy(TM),
the standard of care for the treatment of peripheral nerve conditions. It is
currently approved in Europe and Canada for temporary wrinkle reduction,
temporary pain reduction and treatment of dermatologic conditions. The
myoscience technology has also been cleared in the United States for use in
pain management and general surgical use. For more information, please visit
www.myoscience.com.
The myoscience logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13581
CONTACT: Alexandra Mack, myoscience inc.
Tel: 00 1 650 421 0609
amack(at)myoscience.com
News Source: NASDAQ OMX
01.02.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: myoscience
United States
Phone:
Fax:E-mail:
Internet:
ISIN: US9902131674
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.02.2013 - 08:00 Uhr
Sprache: Deutsch
News-ID 225303
Anzahl Zeichen: 4763
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 238 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: The World's First Toxin Free Dynamic Wrinkle Treatment is Approved in Europe"
steht unter der journalistisch-redaktionellen Verantwortung von
myoscience (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
